Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. The company was founded in 2019 and is based in Toronto, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.025840747166746655 | N/A |
Market Cap | $2.30M | N/A |
Shares Outstanding | 89.01M | 4.07% |
Employees | 0 | N/A |
Shareholder Equity | 1.33M | -50.79% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.37 | N/A |
P/B Ratio | 1.72 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -3.3657 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$4.49M | N/A |
EPS | -0.07 | N/A |
Earnings Yield | -2.71 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $2.95M | N/A |
Total Debt | $34.76K | N/A |
Cash on Hand | $1.76M | N/A |
Debt to Equity | $1.48 | 229.81% |
Cash to Debt | $50.63 | 1824.42% |
Current Ratio | $1.06 | -55.67% |